Company profilePharmaceutical#36 of 1,318 in Pakistan2 DRAP alerts

Medipak (Pvt) Ltd

Pharmaceutical company · 281 brands · 217 molecules

Ranked #4 of 11 companies in Solutions Affecting The Electrolyte Balance

281 registered products 140 pharmaceutical brands 217 distinct molecules 2 DRAP alerts

Company overview

281
registered products
140
pharmaceutical brands
217
distinct molecules
12
therapeutic classes
2
DRAP alerts

Medipak (Pvt) Ltd is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 281 product registrations across 217 distinct molecules. It is the 36th largest registrant in Pakistan by product count, and ranks 4th of 11 in Solutions Affecting The Electrolyte Balance. Its portfolio is concentrated in Solutions Affecting The Electrolyte Balance and Peritoneal Dialytics. DRAP has issued 2 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Medipak

123 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

117
ceilings with an approval date
1
not revised in 2+ years
2024
oldest approval year
20241
202595
202621
Longest without revision

Top molecules by brand count

Eye23 brands
Chloride6 brands
Paracetamol5 brands
Sodium5 brands
Peritoneal Dialysis Solution5 brands

Therapeutic classes

Solutions Affecting The Electrolyte Balance · 8Peritoneal Dialytics · 8Antiinflammatory Agents And Antiinfectives In Combination · 7Anti-Infective, Ophthalmologicals · 5Antiglaucoma Preparations And Miotics · 4Decongestants And Antiallergics · 3Solutions For Parenteral Nutrition · 3Mydriatics And Cycloplegics · 3Eye Conditions · 3Irrigating Solutions · 2Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 2Macrolides, Lincosamides And Streptogramins · 2

Conditions treated

Allergy/Infections · 2Liver/Kidney/Stone · 1Glaucoma/Mydriasis · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official273 products · Rs 2.1 – Rs 1,348,616.25
DVAGO5 products · Rs 35.75 – Rs 190
Servaid4 products · Rs 109 – Rs 3,895
Median across source: Rs 168.13

Regulatory record

2 alerts in the DRAP feed we track.

Recall Alert: Recall Notices for 7 products Issued By Provincial Drug Testing Laboratories
2024-11-29
Drug Product Recall: Dextrose 25% Infusion (Batch# A042C21) by M/s Otsuka Pakistan Ltd, Hu
2021-12-28

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD. holds 130 molecules not in this portfolio
AlbuterolAmikacinAminophyllineAmlodipineAmlodipine BaseAmmonium Chloride
Atco Pharma International (Pvt) Ltd holds 208 molecules not in this portfolio
Acetylsalicylic AcidAcyclovirAdapaleneAdapleneAlbuterolAminophylline
SEARLE PAKISTAN (PVT.) LTD. holds 208 molecules not in this portfolio
AcetazolamideAdalimumabAlprazolamAmilorideAminophyllineAmitriptyline

Get the full profile for Medipak

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.